Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

(2017) Peter C. Taylor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term outcomes of treat-to-target strategy in established rheumatoid arthritis: a daily practice prospective cohort study

(2017) Nicole Pamplona Bueno de Andrade et al.   RHEUMATOLOGY INTERNATIONAL

Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial

(2016) James Dale et al.   ANNALS OF THE RHEUMATIC DISEASES

Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial

(2016) Espen A Haavardsholm et al.   BMJ-British Medical Journal

Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial

(2016) Espen A Haavardsholm et al.   BMJ-British Medical Journal

Response to: 'The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region’ by Rinaudo-Gaujouset al

(2015) K A van Schie et al.   ANNALS OF THE RHEUMATIC DISEASES

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

(2014) J S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study

(2013) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study

(2012) M. E. Weinblatt et al.   RHEUMATOLOGY

Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial

(2011) V. Strand et al.   ANNALS OF THE RHEUMATIC DISEASES

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

(2011) Roy Fleischmann et al.   ARTHRITIS AND RHEUMATISM

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) D. Aletaha et al.   ANNALS OF THE RHEUMATIC DISEASES

Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial

(2009) M. Soubrier et al.   RHEUMATOLOGY

Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial

(2009) Vibeke Strand et al.   ARTHRITIS RESEARCH & THERAPY

Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature

(2008) K Visser et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies

(2008) E Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

(2008) Edward Keystone et al.   ARTHRITIS AND RHEUMATISM